Notice of Allowability	Application No.	Applicant(s)	
	10/051,320	SHEPARD, H. MICHAEL	
	Examiner	Art Unit	
	Jennifer Kim	1617	
The MAILING DATE of this communication appe All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI of the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication GHTS. This application is subject to	plication. If not included will be mailed in due course	
1. This communication is responsive to <u>May 9, 2006</u> .			
2. X The allowed claim(s) is/are <u>1 and 23</u> .			
<ul> <li>3. Acknowledgment is made of a claim for foreign priority un a) All b) Some* c) None of the:  1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:</li> <li>Applicant has THREE MONTHS FROM THE "MAILING DATE" on the other international bureau to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.</li> <li>4. A SUBSTITUTE OATH OR DECLARATION must be submitinformal part application (PTO-152) which give 5. CORRECTED DRAWINGS (as "replacement sheets") must (a) including changes required by the Notice of Draftsperson 1) hereto or 2) to Paper No./Mail Date  (b) including changes required by the attached Examiner's Paper No./Mail Date  Identifying indical such as the application number (see 37 CFR 1. each sheet. Replacement sheet(s) should be labeled as such in the depose attached Examiner's comment regarding REQUIREMENT Foreign and the properties of the priority documents and the priority of the p</li></ul>	been received.  been received in Application Nocuments have been received in this recei	national stage application from the requirement of the stage application from the requirement of the stage application from the stage application from the front (not the back) of the submitted. Note the submitted of the submitt	ents E OF
<ul> <li>Attachment(s)</li> <li>1. ☐ Notice of References Cited (PTO-892)</li> <li>2. ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)</li> <li>3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No./Mail Date 5/9/2006</li> <li>4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material</li> </ul>	6. ☐ Interview Summary Paper No./Mail Dat 8), 7. ☐ Examiner's Amendn	e	
	SHENGU PRIMARY	UNWANG EXAMINER	

## **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on May 9, 2006 has been entered.

## Communication

Applicants' submission of Supplemental Information Disclosure Statement on May 9, 2006 has been received and carefully considered and the submission does not affect the patentability of the claimed subject matter.

Claims 2, 3, 5-9 and 14-22 have been cancelled without prejudice by Examiner's Amendment mailed February 9, 2006.

Claims 1 and 23 are allowed for the same reasons as indicated in the previous Reasons of Allowance and repeated herein.

## **Reasons for Allowance**

Application/Control Number: 10/051,320

Art Unit: 1617

The following is an examiner's statement of reasons for allowance:

The claims are allowable over the cited prior art because the prior art does not teach, disclose nor make obvious the claimed method for treating a subject having rheumatoid arthritis comprising delivering to the subject an effective amount of an L- or D- compound of the formula set forth in claims 1 and 23.

Cited prior art of record, Lacey et al. is the inventor's own work that was published less than one year before the effective filing date of instant Application and instant inventor has filed 37 C.F.R. 1.132 Declaration that the prior art was published on the inventor's behalf and the instant invention related to the treatment of autoimmune disorder (i.e. rheumatoid arthritis) whereas the prior art of record relates to the treatment of cancer.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jennifer Kim whose telephone number is 571-272-0628. The examiner can normally be reached on Monday through Friday 5:30 am to 2 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreenivasan Padmanabhan can be reached on 571-272-0629. The fax

Application/Control Number: 10/051,320 Page 4

Art Unit: 1617

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jmk May 26, 2006

SHENGJÜN WANG PRIMARY EXAMINER